Change in Director / Key Managerial Personnel
Nature of change: Resignation of Chief Executive Officer (CEO) of material subsidiary
Name and DIN of the individual: Dr. Sridevi Khambhampaty (DIN not disclosed in document)
Effective date and tenure: Resignation effective from closing hours of 15 July 2026. Resignation letter submitted on 15 April 2026 with notice period served until cessation date.
Brief profile and relevant qualifications: Document does not provide specific qualifications or experience details for Dr. Sridevi Khambhampaty.
Confirmation of eligibility: No specific mention of eligibility under SEBI/BSE/NSE norms.
Relationship with other directors: Not disclosed.
Previous KMP: Dr. Sridevi Khambhampaty was the CEO of Shilpa Biologicals Private Limited prior to resignation. No information provided about successor or interim arrangements.
Potential financial impact: Document does not disclose any financial impact assessment of this leadership change. The resignation is attributed to personal reasons.
Key Financial or Operational Approvals
This section does not apply to this data.
Strategic or Business Context
This section does not apply to this data.
Any Other Material Information
Regulatory compliance: Disclosure made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025- CFDPOD2/I/3762/2026 dated 30th January 2026.
Subsidiary status: Shilpa Biologicals Private Limited is confirmed as a material subsidiary of Shilpa Medicare Limited.
Facility reference: Dr. Khambhampaty's resignation letter mentions the "Shilpa Biologicals beautiful facility at Dharwad" and expresses confidence that the company "will flourish in the Biologics business."
Company Contact: Ritu Tiwary, Company Secretary & Compliance Officer of Shilpa Medicare Limited